Ferring expands infertility portfolio by acquiring Novartis' Norprolac

5 January 2004

Denmark's Ferring Pharmaceuticals has concluded a deal with Swiss health care major Novartis for the acquisition of the worldwide manufacturing, marketing and distribution rights to Norprolac (quinagolide). No financial terms of the accord were disclosed.

The agent is a prolactin inhibitor indicated for the management of hyperprolactinemia, a disorder that suppresses ovulation by the production of excess levels of the hormone prolactin, and is a major cause of female infertility. Norprolac is ranked fourth in terms of sales in this disease area, behind Pfizer's cabergoline, Novartis' bromocriptine and Nihon-Schering's terguride, noted Ferring.

The deal will allow Ferring to further expand and diversify its infertility portfolio, which makes up more than one third of its total sales revenue. The firm's other products in this therapeutic area include:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight